Is Neurocrine Biosciences (NBIX) Undervalued On Pipeline And Pricing Risks?
Neurocrine Biosciences (NBIX) has drawn fresh attention after recent trading left the shares around $136.95. The move comes amid mixed recent returns and solid reported revenue and net income figures.
Neurocrine Biosciences shares have lost momentum in recent months, with a 30 day share price return of 8.71% and a 90 day decline of 19.86%. However, the 3 year total shareholder return of 23.23% and 5 year total shareholder return of 31.68% point to a much steadier long run record.
Compare Neurocrine Biosciences with a hand picked group of peers by scanning the 20 high quality undiscovered gems that share strong fundamentals yet still fly under many investors' radar.
Recent weakness around US$136.95 sits against a large implied discount to fair value. Is Neurocrine Biosciences mispriced, or is the market flagging real risks that the valuation work needs to unpack next?
Most Popular Narrative: 18% Undervalued
On the most followed view, Neurocrine Biosciences screens as undervalued, with a Fair Value of $166.59 against the recent close at $136.95. That gap is tied directly to how investors judge product concentration, pricing pressure, and the pipeline’s ability to carry more weight over time.
Even if INGREZZA volumes expand into a relatively underpenetrated tardive dyskinesia population, the expectation of an IRA mandated maximum fair price discount of 25 to 34% off non FAMP starting in 2029, combined with management’s indication that this will likely cause an INGREZZA revenue dip that year, suggests a break in the revenue trajectory of the company’s largest product that could pressure overall earnings and limit cash available for late stage pipeline launches.
See why 1 investors see Neurocrine Biosciences as 18% undervalued.
Result: Fair Value of $166.59 (UNDERVALUED)
Still, the bearish script could unravel if Neurocrine Biosciences sustains near US$1b quarterly revenue momentum, or if VYKAT XR safety concerns ease and support stronger earnings.
Find out about the key risks to this Neurocrine Biosciences narrative.
Next Steps
Mixed views on Neurocrine Biosciences so far. If you want to move quickly and shape your own take, start by checking its 4 key rewards.
Looking for more Neurocrine Biosciences sized investment ideas?
If you stop with Neurocrine Biosciences, you risk missing other opportunities. Put fresh ideas on your radar by scanning focused stock lists built from hard numbers.
- Target income resilience by reviewing steady payers highlighted in the 8 dividend fortresses that combine yield with underlying business strength.
- Spot potential value gaps early by combing through the 33 high quality undervalued stocks where pricing and fundamentals may be out of sync.
- Prioritise capital preservation by starting with the 32 resilient stocks with low risk scores that filters for sturdier balance sheets and more defensive profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com